AVRO VS IXHL Stock Comparison

Performance

AVRO
100/100

AVRO returned 78.43% in the last 12 months. Based on SPY's performance of -12.98%, its performance is above average giving it a score of 100 of 100.

IXHL
10/100

IXHL returned -77.16% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

AVRO
88/100

4 analysts offer 12-month price targets for AVRO. Together, they have an average target of 0, the most optimistic target put AVRO at 0 within 12-months and the most pessimistic has AVRO at 0.

IXHL

"Analyst Price Targets" not found for IXHL

Technicals

AVRO
25/100

AVRO receives a 25 of 100 based on 14 indicators. 3 are bullish, 10 are bearish.

IXHL
10/100

IXHL receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

Earnings

AVRO
10/100

AVRO has missed earnings 13 times in the last 20 quarters.

IXHL

"Earnings" not found for IXHL

Profit

AVRO
10/100

Out of the last 20 quarters, AVRO has had 1 profitable quarters and has increased their profits year over year on 1 of them.

IXHL
10/100

Out of the last 20 quarters, IXHL has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

AVRO
25/100

AVRO has had a lower than average amount of volatility over the last 12 months giving it a score of 25 of 100.

IXHL
38/100

IXHL has had a lower than average amount of volatility over the last 12 months giving it a score of 37 of 100.

All score calculations are broken down here to help you make more informed investing decisions

AVROBIO, Inc. Common Stock Summary

Nasdaq / AVRO

Healthcare

Biotechnology

AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Incannex Healthcare Limited American Depositary Shares Summary

Nasdaq / IXHL

Healthcare

Drug Manufacturers - Specialty & Generic

Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name. The company's products include IHL-42X, which is in Phase II clinical trials for obstructive sleep apnea; IHL-216A for traumatic brain injury; and IHL-675A, a combination of hydroxychloroquine and cannabidiol for the prevention and treatment of inflammatory lung conditions, such as acute respiratory distress syndrome, chronic obstructive pulmonary disease, asthma, and bronchitis, as well as rheumatoid arthritis and inflammatory bowel diseases. It has partnership with The Alfred Hospital and Novotech on IHL-42X clinical program for obstructive sleep apnea; and Monash Trauma Group at the Department of Neuroscience, Monash University to conduct a study on the protective effect of IHL-216A in sports concussion. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited was incorporated in 2001 and is based in Sydney, Australia.

Power up your portfolio